In patients with non-small cell lung cancer, V. dispar is predominated in groups with high levels of programmed cell death-ligand 1 (PD-L1), which are responders to immunotherapy, proving that the composition of the lung microbiome may influence disease development as well as treatment efficacy (Jang et al., 2021). Here, CD274 is linked to non-small cell lung carcinoma.